Loading...

Home
ETF
MBRX

MBRX

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press

Markets

Market Analysis
Crypto
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

AI Strategies

AI Stock Picker
Swing Trading
SwingMax Portfolio
Quant AI Alpha Pick
CoinSwing
Daytrading Center
Crypto Radar
Patterns Detection

Resources

Blog
Tutorial
Help Center
Affiliate Program

Products

Chat With Tia
AI Screener
Backtest Playground
Featured Screeners
AI Earnings Calendar
Thematic Investing
Whales Auto Tracker

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

Explore AI Stock Picker
Master Swing Trading
Follow SwingMax Portfolio
Discover QuantAI Alpha Pick
Follow Whales Auto Tracker
Navigate Daytrading Center
Learn Patterns Detection
Meet Financial AI Agent
Maximize AI Screener
Why Backtesting Playground
Forecast AI Earnings Prediction
Setup Stock Monitor
Deep Dive into Tech Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

MBRX News

Moleculin Launches CEO Corner Platform for Investor Insights

2d agoNewsfilter

Moleculin Biotech's 2026 MIRACLE Trial Data Unblinding Expected

Jan 12 2026Globenewswire

Moleculin Stock Falls 17% Despite Encouraging Phase 1 WP1066 Results for Pediatric Brain Tumors

Dec 17 2025NASDAQ.COM

Moleculin's WP1066 Demonstrates Immune Response and Positive Safety Profile in Pediatric Brain Cancer Study

Dec 17 2025NASDAQ.COM

Moleculin Biotech Increases Enrollment to 78% for MIRACLE Trial

Dec 09 2025Globenewswire

Moleculin Biotech Increases Enrollment to 78% for MIRACLE Trial

Dec 09 2025Newsfilter

Moleculin Biotech to Showcase Company Overview in Virtual Investor Closing Bell Series

Nov 28 2025NASDAQ.COM

Moleculin Biotech CEO to Host Investor Webcast on December 2, 2025

Nov 26 2025Newsfilter

Moleculin Biotech Announces 1-for-25 Reverse Stock Split, Reducing Outstanding Shares to 2.1 Million

Nov 26 2025Newsfilter

Moleculin Biotech Executes 1-for-25 Reverse Stock Split, Reducing Shares to 2.1 Million

Nov 26 2025Globenewswire

Moleculin Announces 60% Consent Rate Among First 45 Participants in Pivotal "MIRACLE" Phase 3 AML Trial

Nov 13 2025Newsfilter

Moleculin Unveils Funded Research on Annamycin's Potential for Treating Pancreatic Cancer at UNC-Chapel Hill

Nov 12 2025Newsfilter

Moleculin to Showcase Its Ongoing Phase 3 "MIRACLE" Clinical Trial for Acute Myeloid Leukemia at the 14th Annual Acute Leukemia Meeting

Oct 30 2025Newsfilter

Innovative Approaches to Address Challenging Medical Conditions Beyond Conventional Medications

Oct 21 2025Newsfilter

Moleculin Biotech (MBRX) Receives Upgrade to Buy: Key Information You Need to Know

Sep 17 2025NASDAQ.COM

HC Wainwright & Co. Affirms Buy Rating for Moleculin Biotech, Keeps $4 Price Target Intact

Sep 10 2025Benzinga